α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease

Human Molecular Genetics

Volumn 21, Issue 3, 2012, Pages 495-510

  Tomás Zapico, Cristina ^a,b,f   Díez Zaera, María ^c   Ferrer, Isidre ^b,d   Gómez Ramos, Pilar ^e   Morán, María A ^e   Teresa Miras Portugal, M ^c   Díaz Hernández, Miguel ^c   Lucas, José J ^a,b  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^f UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; HUNTINGTIN; POLYGLUTAMINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN ATROPHY; CELL INCLUSION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; EXON; GENE INACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NEUROFILAMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ROTAROD TEST; SURVIVAL; THROMBOCYTE AGGREGATION; WEIGHT REDUCTION;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; ATROPHY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; LONGEVITY; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUTATION; NEOSTRIATUM; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHENOTYPE; WEIGHT LOSS;

MUS;

EID: 84856094308     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr507     Document Type: Article

References (60)

1. Orr, H.T. and Zoghbi, H.Y. (2007) Trinucleotide repeat disorders. Annu. Rev. Neurosci., 30, 575-621.
2. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
3. Ross, C.A. (1997) Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron, 19, 1147-1150.
4. Ross, C.A. and Poirier, M.A. (2004) Protein aggregation and neurodegenerative disease. Nat. Med., 10 (suppl.), S10-S17.
5. Gidalevitz, T., Ben-Zvi, A., Ho, K.H., Brignull, H.R. and Morimoto, R.I. (2006) Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science, 311, 1471-1474.
6. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M. and Sudhof, T.C. (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 123, 383-396.
7. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R. and Sudhof, T.C. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 329, 1663-1667.
8. Giasson, B.I., Uryu, K., Trojanowski, J.Q. and Lee, V.M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem., 274, 7619-7622.
9. Dickson, D.W. (2001) Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol., 14, 423-432.
10. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA, 95, 6469-6473.
11. Conway, K.A., Harper, J.D. and Lansbury, P.T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 4, 1318-1320.
12. Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem., 274, 9843-9846.
13. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
14. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
15. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173.
16. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
17. Charles, V., Mezey, E., Reddy, P.H., Dehejia, A., Young, T.A., Polymeropoulos, M.H., Brownstein, M.J. and Tagle, D.A. (2000) Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci. Lett., 289, 29-32.
18. Alves, S., Regulier, E., Nascimento-Ferreira, I., Hassig, R., Dufour, N., Koeppen, A., Carvalho, A.L., Simoes, S., de Lima, M.C., Brouillet, E. et al. (2008) Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet., 17, 2071-2083.
19. Berciano, J. and Ferrer, I. (2005) Glial cell cytoplasmic inclusions in SCA2 do not express alpha-synuclein. J. Neurol., 252, 742-744.
20. Furlong, R.A., Narain, Y., Rankin, J., Wyttenbach, A. and Rubinsztein, D.C. (2000) Alpha-synuclein overexpression promotes aggregation of mutant huntingtin. Biochem. J., 346 (Pt 3), 577-581.
21. Winslow, A.R., Chen, C.W., Corrochano, S., Acevedo-Arozena, A., Gordon, D.E., Peden, A.A., Lichtenberg, M., Menzies, F.M., Ravikumar, B., Imarisio, S. et al. (2010) α-Synuclein impairs macroautophagy: implications for Parkinson's disease. J. Cell Biol., 190, 1023-1037.
22. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
23. Diaz-Hernandez, M., Moreno-Herrero, F., Gomez-Ramos, P., Moran, M.A., Ferrer, I., Baro, A.M., Avila, J., Hernandez, F. and Lucas, J.J. (2004) Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J. Neurosci., 24, 9361-9371.
24. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
25. DiFiglia, M., Sapp, E., Chase, K., Davies, S., Bates, G., Vonsattel, J. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
26. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-548.
27. Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M. and Ross, C.A. (2002) Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrillization. J. Biol. Chem., 277, 41032-41037.
28. Conway, K.A., Harper, J.D. and Lansbury, P.T. Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 39, 2552-2563.
29. Ross, C.A. and Poirier, M.A. (2005) Opinion: what is the role of protein aggregation in neurodegeneration? Nat. Rev., 6, 891-898.
30. Scherzinger, E., Sittler, A., Schweiger, K., Heiser, V., Lurz, R., Hasenbank, R., Bates, G.P., Lehrach, H. and Wanker, E.E. (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl Acad. Sci. USA, 96, 4604-4609.
31. Maynard, C.J., Bottcher, C., Ortega, Z., Smith, R., Florea, B.I., Diaz-Hernandez, M., Brundin, P., Overkleeft, H.S., Li, J.Y., Lucas, J.J. et al. (2009) Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. Proc. Natl Acad. Sci. USA, 106, 13986-13991.
32. Chopra, V., Fox, J.H., Lieberman, G., Dorsey, K., Matson, W., Waldmeier, P., Housman, D.E., Kazantsev, A., Young, A.B. and Hersch, S. (2007) A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl Acad. Sci. USA, 104, 16685-16689.
33. van Dellen, A., Blakemore, C., Deacon, R., York, D. and Hannan, A.J. (2000) Delaying the onset of Huntington's in mice. Nature, 404, 721-722.
34. Naver, B., Stub, C., Moller, M., Fenger, K., Hansen, A.K., Hasholt, L. and Sorensen, S.A. (2003) Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience, 122, 1049-1057.
35. Rubio, I., Rodriguez-Navarro, J.A., Tomas-Zapico, C., Ruiz, C., Casarejos, M.J., Perucho, J., Gomez, A., Rodal, I., Lucas, J.J., Mena, M.A. et al. (2009) Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. Brain Res., 1281, 91-100.
36. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
37. Pallier, P.N., Drew, C.J. and Morton, A.J. (2009) The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: influence of non-motor factors on locomotor function. Brain Res. Bull., 78, 347-355.
38. Rajan, R.S., Illing, M.E., Bence, N.F. and Kopito, R.R. (2001) Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl Acad. Sci. USA, 98, 13060-13065.
39. Paxinou, E., Chen, Q., Weisse, M., Giasson, B.I., Norris, E.H., Rueter, S.M., Trojanowski, J.Q., Lee, V.M. and Ischiropoulos, H. (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci., 21, 8053-8061.
40. Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H. and Wanker, E.E. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell, 12, 1393-1407.
41. Lamark, T. and Johansen, T. (2010) Autophagy: links with the proteasome. Curr. Opin. Cell Biol., 22, 192-198.
42. Jana, N.R., Zemskov, E.A., Wang, G. and Nukina, N. (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum. Mol. Genet., 10, 1049-1059.
43. Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-1555.
44. Diaz-Hernandez, M., Valera, A.G., Moran, M.A., Gomez-Ramos, P., Alvarez-Castelao, B., Castano, J.G., Hernandez, F. and Lucas, J.J. (2006) Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J. Neurochem., 98, 1585-1596.
45. Diaz-Hernandez, M., Hernandez, F., Martin-Aparicio, E., Gomez-Ramos, P., Moran, M.A., Castano, J.G., Ferrer, I., Avila, J. and Lucas, J.J. (2003) Neuronal induction of the immunoproteasome in Huntington's disease. J. Neurosci., 23, 11653-11661.
46. Bett, J.S., Cook, C., Petrucelli, L. and Bates, G.P. (2009) The ubiquitinproteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. PLoS One, 4, e5128.
47. Ortega, Z., Diaz-Hernandez, M., Maynard, C.J., Hernandez, F., Dantuma, N.P. and Lucas, J.J. (2010) Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J. Neurosci., 30, 3675-3688.
48. Wang, J., Wang, C.E., Orr, A., Tydlacka, S., Li, S.H. and Li, X.J. (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J. Cell Biol., 180, 1177-1189.
49. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A. and Krainc, D. (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146, 37-52.
50. Trojanowski, J.Q. (2002) Emerging Alzheimer's disease therapies: focusing on the future. Neurobiol. Aging, 23, 985-990.
51. Duda, J.E., Giasson, B.I., Mabon, M.E., Miller, D.C., Golbe, L.I., Lee, V.M. and Trojanowski, J.Q. (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol., 104, 7-11.
52. Giasson, B.I., Forman, M.S., Higuchi, M., Golbe, L.I., Graves, C.L., Kotzbauer, P.T., Trojanowski, J.Q. and Lee, V.M. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science, 300, 636-640.
53. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M. and Mucke, L. (2001) Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA, 98, 12245-12250.
54. Furukawa, Y., Kaneko, K., Matsumoto, G., Kurosawa, M. and Nukina, N. (2009) Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J. Neurosci., 29, 5153-5162.
55. Krammer, C., Kremmer, E., Schatzl, H.M. and Vorberg, I. (2008) Dynamic interactions of Sup35p and PrP prion protein domains modulate aggregate nucleation and seeding. Prion, 2, 99-106.
56. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P. Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
57. Vonsattel, J.P. and DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
58. Specht, C.G. and Schoepfer, R. (2001) Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci., 2, 11.
59. Lucas, J.J., Hernandez, F., Gomez-Ramos, P., Moran, M.A., Hen, R. and Avila, J. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J., 20, 27-39.
60. Martin-Aparicio, E., Yamamoto, A., Hernandez, F., Hen, R., Avila, J. and Lucas, J.J. (2001) Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci., 21, 8772-8781.